Welcome to our dedicated page for Dyadic Intl Del news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic Intl Del stock.
Dyadic International, Inc. (Nasdaq: DYAI), doing business as Dyadic Applied BioSolutions, regularly issues news on its activities as a global biotechnology company producing precision-engineered, animal-free proteins and enzymes. This news page aggregates press releases and market updates that describe how Dyadic is advancing its microbial C1 and Dapibus™ expression platforms across life sciences, food and nutrition, and bio-industrial markets.
Readers can find announcements about commercial agreements and partnerships, such as collaborations with Proliant Health and Biologicals, Inzymes ApS, Fermbox Bio, BRIG BIO, and Opes Diagnostics. These items often cover milestones in recombinant serum albumin, transferrin, growth factors, non-animal dairy proteins, and industrial enzyme products like EN3ZYME™, as well as details on licensing structures, milestone payments, and revenue-sharing arrangements.
Dyadic’s news flow also includes financial results and corporate developments, including quarterly earnings releases, equity offerings, and updates on its strategic shift from a research-driven organization to a commercially focused biotechnology company. These releases highlight progress in expanding product pipelines, scaling manufacturing, and strengthening liquidity to support commercial growth.
Another recurring theme in DYAI news is technology and platform validation. Articles describe grant-funded programs with organizations such as the Bill & Melinda Gates Foundation and CEPI, peer-reviewed publications demonstrating the capabilities of the C1 platform for vaccine antigens, and the CRISPR/Cas9 license agreement with ERS Genomics that broadens Dyadic’s genetic engineering toolkit.
Investors, analysts, and industry participants can use this page to follow Dyadic’s evolving portfolio of recombinant proteins, its regional expansion efforts, and its responses to Nasdaq listing matters disclosed in SEC filings. Bookmark this section to review the company’s historical and ongoing news as it reports commercial milestones, scientific progress, and capital markets activity.
Dyadic International (NASDAQ: DYAI) announced its participation in the 2022 H.C. Wainwright Global Investment Conference held from May 23-26, 2022, at the Fontainebleau Miami Beach Hotel. President and CEO, Mark Emalfarb, will present on May 25, 2022, at 12:30 PM ET. The management team will also host one-on-one meetings, accessible through a request at hzosiak@dyadic.com. Dyadic focuses on developing its proprietary C1-cell protein production platform to enhance the efficiency and cost-effectiveness of biologic vaccines and drugs.
Dyadic International (NASDAQ: DYAI) reported a 40.8% revenue increase in Q1 2022, reaching approximately $534,000. The company secured a new collaboration with a global food ingredients firm and a license deal with Phibro for animal vaccines. Positive developments include advancing a first-in-human clinical trial application for the DYAI-100 COVID-19 vaccine in South Africa, while a C1-produced antibody showed efficacy against Omicron variants. Cash and investments stood at $17.5 million as of March 31, 2022, against a net loss of approximately $2.49 million.
Dyadic International, Inc. (NASDAQ: DYAI) has entered into a Joint Development Agreement with a Global Food Ingredients Company to produce animal-free ingredient products. The project is fully funded with €3.6 million. Dyadic will develop proprietary production cell lines and can earn success and commercialization fees, along with royalties on sales. This partnership illustrates Dyadic's capacity to leverage its C1 protein production platform beyond biopharmaceuticals, tapping into emerging markets and enhancing its value in biomanufacturing.
Dyadic International announced positive results from a toxicology study of its COVID-19 vaccine candidate, DYAI-100, published in Toxicologic Pathology. The study revealed an excellent safety profile and strong immunogenic responses in animal models. The findings support Dyadic’s upcoming First-In-Human clinical trial and validate its C1-cell protein production platform, which aims to lower biopharmaceutical production costs. This marks Dyadic's third peer-reviewed publication in 2022 regarding the efficacy and safety of its products.
Dyadic International, Inc. (NASDAQ: DYAI) announced its upcoming financial results report for Q1 2022, scheduled for May 12, 2022, at 5:00 p.m. ET. The company specializes in using its proprietary C1-cell protein production platform to enhance the development and production of biologic drugs and vaccines at lower costs. The conference call will discuss financial performance and future strategies, accessible via specific dial-in numbers or a webcast link. Dyadic aims to leverage its C1 technology to improve access to biologics and save lives.
Dyadic International, Inc. (NASDAQ: DYAI) announced that its licensee, Epygen Biotech, received funding from India's Department of Biotechnology to support Phase 1 and 2 clinical trials of a COVID-19 vaccine using Dyadic's C1 protein production platform. Epygen aims to develop a low-cost vaccine, anticipated to be priced around $2 per dose, targeting the production of 100 million doses annually. Additionally, Epygen plans to raise $26 million for Phase 3 trials to enhance production capacity and expedite vaccine availability.
Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced its participation in key scientific meetings in April 2022. The company will present its proprietary C1-cell protein production platform aimed at enhancing biologic vaccine and drug development during the Microbial Engineering II conference in Portugal and the World Vaccine Congress in Washington, DC. Presentations will cover topics including therapeutic protein production and innovative vaccine manufacturing solutions, showcasing how C1 can reduce costs and improve efficiency in biopharmaceuticals.
Dyadic International (NASDAQ: DYAI) announced substantial developments, including a collaboration with Janssen for therapeutic proteins, securing a $690,000 NIIMBL grant, and a license agreement with Phibro Animal Health for vaccines. The company anticipates advancing its DYAI-100 COVID-19 vaccine toward human trials. Financial highlights reveal a 50% increase in R&D revenue to $2.4 million for 2021, although the net loss rose to approximately $13.1 million. Cash and investments stood at $20.4 million, down from $29.2 million in 2020.
Dyadic International, a biotechnology firm (NASDAQ: DYAI), announced it will report its 2021 financial results and host a corporate update conference call on March 29, 2022. The company is focused on its proprietary C1-cell protein platform, which aims to lower production costs and enhance biologic vaccine and drug development. The conference will be accessible via dial-in or webcast, providing shareholders an opportunity to stay informed about the company's operations and future prospects.
Dyadic International and Phibro Animal Health have entered an exclusive license agreement to utilize Dyadic's C1-cell protein production platform for developing a poultry vaccine targeting a specific disease. This partnership follows successful proof of concept animal trials. The agreement allows Phibro to produce targeted antigens for vaccine commercialization. Both companies plan to continue their collaboration to develop additional animal vaccine candidates, thereby enhancing the efficiency of vaccine production.